Related Experiment Video
Updated: Aug 9, 2026
08:01
Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
Alzheimer's disease: interactions between cholinergic functions and beta-amyloid
1Dept. of Physiology and Biophysics, State University of New York at Buffalo, School of Medicine and Biomedical Sciences, Buffalo, NY 14214, USA. zhenyan@buffalo.edu
Current Alzheimer Research
|June 25, 2005
Summary
Alzheimer's disease involves cholinergic neuron loss and beta-amyloid buildup, impacting cognition. This review explores their interaction, offering insights into Alzheimer's disease pathophysiology and treatment strategies.
Area of Science:
- Neuroscience
- Pathophysiology
- Pharmacology
Background:
- Alzheimer's disease (AD) features cholinergic neuron degeneration and beta-amyloid (Abeta) plaque formation, both linked to cognitive decline.
- Enhancing cholinergic transmission is a key therapeutic strategy for AD, targeting muscarinic acetylcholine receptors (mAChRs) crucial for cognition.
- The interplay between Abeta's detrimental effects and cholinergic system dysfunction in AD pathogenesis remains incompletely understood.
Purpose of the Study:
- To review recent findings on the interactions between cholinergic functions and Abeta.
- To discuss the implications of these interactions in Alzheimer's disease pathophysiology.
- To explore potential therapeutic targets based on these interactions.
Main Methods:
- Literature review of studies on cholinergic function and Abeta.
- Analysis of data from normal animal models and Alzheimer's disease models.
- Synthesis of findings to elucidate disease mechanisms.
Main Results:
- Cholinergic deficits and Abeta accumulation are key AD hallmarks.
- Muscarinic receptor agonists show potential in improving cognitive deficits.
- Abeta exerts detrimental effects on cognitive functions.
Conclusions:
- Understanding the interaction between cholinergic systems and Abeta is vital for AD research.
- Targeting mAChRs and mitigating Abeta effects may offer synergistic therapeutic benefits.
- Further research into these interactions can advance Alzheimer's disease treatment strategies.
Related Concept Videos
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...